Sirukumab for rheumatoid arthritis: The phase III SIRROUND-D study

Annals of the Rheumatic Diseases

Volumn 76, Issue 12, 2017, Pages 2001-2008

  Takeuchi, Tsutomu ^a   Thorne, Carter ^b   Karpouzas, George ^c   Sheng, Shihong ^d   Xu, Weichun ^d   Rao, Ravi ^e   Fei, Kaiyin ^d   Hsu, Benjamin ^d   Tak, Paul P ^e  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF TORONTO   (Canada)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

cytokines; DMARDs (biologic); DMARDs (synthetic); rheumatoid arthritis; treatment

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SIRUKUMAB; ANTIRHEUMATIC AGENT; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BRONCHITIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAS28; DIGESTIVE SYSTEM PERFORATION; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG SAFETY; FEMALE; FUNCTIONAL STATUS; HEADACHE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LEUKOPENIA; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PHYSICAL CAPACITY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; AGED; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85037601464     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211328     Document Type: Article

References (20)

1. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005;23:1-21.
2. T ak PP, Smeets TJ, Daha MR, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997;40:217-25.
3. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33:305-15.
4. Guerne PA, Zuraw BL, Vaughan JH, et al. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest 1989;83:585-92.
5. Flannery CR, Little CB, Hughes CE, et al. IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol 2000;19:549-53.
6. X u Z, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 2011;72:270-81.
7. N emeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6.
8. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002;13:357-68.
9. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebocontrolled trial. Ann Rheum Dis 2008;67:1516-23.
10. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88-96.
11. N ishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7.
12. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
13. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol 2015;67:1424-37.
14. Aletaha D, Bingham CO, Tanaka Y, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): A randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet 2017;389:1206-17.
15. T akeuchi T, Tanaka Y, Yamanaka H, et al. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod Rheumatol 2016;26:15-23.
16. Weinblatt ME, Mease P, Mysler E, et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol 2015;67:2591-600.
17. Smolen JS, Weinblatt ME, Sheng S, et al. Sirukumab, a human anti-interleukin-6 monoclonal antibody: A randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2014;73:1616-25.
18. Fleischmann RM, Halland AM, Brzosko M, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol 2013;40:113-26.
19. Kivitz A, Olech E, Borofsky M, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res 2014;66:1653-61.
20. Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rin patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RAMOBILITY Part A trial. Ann Rheum Dis 2014;73:1626-34.